跳至主要内容
临床试验/NCT03136822
NCT03136822已完成不适用

Clinical Evaluation of the Wound Dressing Impregnated With Microparticules (DERMALIX) on Diabetic Foot Ulcers

Dermis Pharma2 个研究点 分布在 1 个国家目标入组 48 人开始时间: 2017年4月26日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
已完成
发起方
Dermis Pharma
入组人数
48
试验地点
2
主要终点
Recovery of the wound 100%

研究概览

简要总结

(DERMALIX) (Patent number: PCT/TR2014/000251) is a bioactive wound dressing that was developed by Ege University School of Pharmacy Department of Pharmaceutical Technology. This dressing has been categorised as Class III medical device. This clinical study will be conducted in patients with diabetic foot ulcers.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Single (Outcomes Assessor)

盲法说明

The wound will be assessed by Pathologists who are masked for treatment

入排标准

年龄范围
18 Years 至 80 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Type 1 or 2 Patients diagnosed with diabetic foot ulcers
  • Class I and II according to Wagner classification
  • No infections confirmed with culture test
  • No osteomyelitis and gangrene in the foot
  • HbA1c values ≤ % 7.5
  • Not active smoker
  • No planned treatment of hyperbaric oxygen
  • Patients who give consent for the study

排除标准

  • Patients with diabetic foot ulcer of class 3,4 and 5 according to Wagner classification
  • Patients who are pregnant or breast-feeding or female who are in reproductive age applying no preservative method
  • Patients who have mental conditions that lead to difficulties in comprehension
  • Patients who may have compliance issues
  • Patients who have been included to another interventional study with drug or medical device

研究组 & 干预措施

Control

Other

Standard dressing

干预措施: Standard Dressing (Other)

Treatment

Experimental

Standard dressing + Wound dressing (DERMALIX)

干预措施: Standard Dressing (Other)

Treatment

Experimental

Standard dressing + Wound dressing (DERMALIX)

干预措施: DERMALIX (Device)

结局指标

主要结局

Recovery of the wound 100%

时间窗: 1 month

The wound will be completely recovered

次要结局

  • Recovery of the wound 80%(1 month)

研究者

发起方
Dermis Pharma
申办方类型
Industry
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验